IL1A and hydrops fetalis: The extension phase of the CANTOS study [Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)], a randomized double-blind trial, suggests Il-1 as a potential therapeutic target in HF.